16 – 22 of 22
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2000
-
Mark
Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
(
- Contribution to journal › Article
-
Mark
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
(
- Contribution to journal › Article
- 1999
-
Mark
Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience
(
- Contribution to journal › Article
-
Mark
Predictive value of P53, MDM-2, P21-expression, KI-67 for response to docetaxel or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictive value c-erB-B2 expression for response to docetaxel (D) or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
- « previous
- 1
- 2
- next »